KNOXVILLE, Tenn., May 3 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today that CEO Craig Dees, Ph.D. is scheduled to make investor presentations at several upcoming investment community events as part of the Company’s ongoing program to introduce the Company to new and broader audiences of institutional investors and other investment community professionals.
These events include presentations at luncheon meetings of investment professionals in the following cities on the dates indicated -- in Portland, May 11; in Seattle, May 17; in Pasadena, CA, May 31; in Newport Beach, CA, June 1; in Naples, FL, June 7; in Houston, June 14; in Austin, TX, June 21; in Cleveland, June 28 and Cincinnati, July 12. In addition, Dr. Dees is scheduled to present at the SCIA National Small Cap Syndicate Capital Conference on Saturday, June 3, in Irvine, CA.
For more information on these events, please contact Jill Bertotti at 949-474-4300 or jill@allencaron.com
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc. is an innovative biopharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company’s topical agent Xantryl(TM), a treatment for psoriasis.
The Company’s offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865 769 4011. For more information, contact the Company at info@pvct.com or visit the corporate Web site: http://www.pvct.com.
This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.
Provectus Pharmaceuticals, Inc.
CONTACT: Peter Culpepper of Provectus Pharmaceuticals, +1-865-769-4011,culpepper@pvct.com; or Matt Clawson (investors) of Allen & Caron Inc,+1-949-474-4300, matt@allencaron.com
Web site: http://www.pvct.com/
